Early elderly male with type 2 diabetes (T2D) changed from metformin to imeglimin (Twymeeg)

Bando H, Okada M, Iwatsuki N, Sakamoto K and Ogawa T

Published on: 2023-02-05

Abstract

Background: Imeglimin (Twymeeg) is latest focus of oral hypoglycemic agent (OHA).

Case presentation: Current case is 69-year-old male with type 2 diabetes (T2D) for 18 years.

Result: HbA1c value increased to 7.6% in Sept 2022, and then metformin 750mg/day was changed to imeglimin 2000mg/day. HbA1c decreased to 6.9% for 4 months.

Discussion and conclusion: Large study of Trials of IMeglimin for Efficacy and Safety (TIMES) showed beneficial efficacy for combined treatment of OHAs. Imeglimin has dual effects increasing insulin secretion and reducing insulin resistance. Perspectives concerning pharmacological effects of metformin and imeglimin are described in diabetic practice and research.